Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance

OBJECTIVES: Raltegravir is the first integrase strand transfer inhibitor approved for treating HIV-1 infection. Although emerging data suggest that raltegravir may also be useful for HIV-2 treatment, studies addressing the in-vitro susceptibility of HIV-2 to raltegravir are scarce, and the genetic p...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Smith, Robert A., Raugi, Dana N., Kiviat, Nancy B., Hawes, Stephen E., Mullins, James I., Sow, Papa S., Gottlieb, Geoffrey S.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3652615/
https://ncbi.nlm.nih.gov/pubmed/21971360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0b013e32834d8e52
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki